Fig. 3From: Bioequivalence trials for the approval of generic drugs in Saudi Arabia: a descriptive analysis of design aspectsCVw vs. trial’s sample size. CVw≤30%: Trials of active pharmaceutical ingredients with CVw≤30%. . CVw>30%: Trials of active pharmaceutical ingredients with CVw>30% Back to article page